1
|
Miao J, Li R, Wettere AJV, Guo H, Tabaran AF, O'Sullivan MG, Carlson T, Scott PM, Chen K, Gao D, Li H, Wang Y, Wang Z, Cormier RT. Cancer spectrum in TP53-deficient golden Syrian hamsters: A new model for Li-Fraumeni syndrome. J Carcinog 2021; 20:18. [PMID: 34729050 PMCID: PMC8531574 DOI: 10.4103/jcar.jcar_18_21] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/28/2021] [Revised: 09/27/2021] [Accepted: 07/23/2021] [Indexed: 12/17/2022] Open
Abstract
Background: The TP53 tumor suppressor gene is the most commonly mutated gene in human cancers. Humans who inherit mutant TP53 alleles develop a wide range of early onset cancers, a disorder called Li-Fraumeni Syndrome (LFS). Trp53-deficient mice recapitulate most but not all of the cancer phenotypes observed in TP53-deficient human cancers, indicating that new animal models may complement current mouse models and better inform on human disease development. Materials and Methods: The recent application of CRISPR/Cas9 genetic engineering technology has permitted the emergence of golden Syrian hamsters as genetic models for wide range of diseases, including cancer. Here, the first cancer phenotype of TP53 knockout golden Syrian hamsters is described. Results: Hamsters that are homozygous for TP53 mutations become moribund on average ~ 139 days of age, while hamsters that are heterozygous become moribund at ~ 286 days. TP53 homozygous knockout hamsters develop a wide range of cancers, often synchronous and metastatic to multiple tissues, including lymphomas, several sarcomas, especially hemangiosarcomas, myeloid leukemias and several carcinomas. TP53 heterozygous mutants develop a more restricted tumor spectrum, primarily lymphomas. Conclusions: Overall, hamsters may provide insights into how TP53 deficiency leads to cancer in humans and can become a new model to test novel therapies.
Collapse
Affiliation(s)
- Jinxin Miao
- Department of Animal, Dairy, and Veterinary Sciences, Utah State University, Logan, Utah, USA.,Sino-British Research Centre for Molecular Oncology, National Centre for International Research in Cell and Gene Therapy, Academy of Medical Sciences, Zhengzhou University, Henan, China.,Academy of Chinese Medical Sciences, Henan University of Chinese Medicine, Henan, China
| | - Rong Li
- Department of Animal, Dairy, and Veterinary Sciences, Utah State University, Logan, Utah, USA
| | - Arnaud J Van Wettere
- Department of Animal, Dairy, and Veterinary Sciences, Utah State University, Logan, Utah, USA
| | - Haoran Guo
- Sino-British Research Centre for Molecular Oncology, National Centre for International Research in Cell and Gene Therapy, Academy of Medical Sciences, Zhengzhou University, Henan, China
| | - Alexandru-Flaviu Tabaran
- College of Veterinary Medicine, University of Minnesota, St. Paul, MN, USA.,Masonic Cancer Center, Comparative Pathology Shared Resource, University of Minnesota, Minneapolis, USA.,Department of Pathology, Faculty of Veterinary Medicine, University of Agricultural Science and Veterinary Medicine Cluj-Napoca, Romania
| | - M Gerald O'Sullivan
- College of Veterinary Medicine, University of Minnesota, St. Paul, MN, USA.,Masonic Cancer Center, Comparative Pathology Shared Resource, University of Minnesota, Minneapolis, USA
| | - Timothy Carlson
- College of Veterinary Medicine, University of Minnesota, St. Paul, MN, USA.,Masonic Cancer Center, Comparative Pathology Shared Resource, University of Minnesota, Minneapolis, USA
| | - Patricia M Scott
- Department of Biomedical Sciences, University of Minnesota Medical School, Duluth, MN, USA
| | - Kuisheng Chen
- Department of Pathology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China
| | - Dongling Gao
- Department of Pathology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China
| | - Huixiang Li
- Department of Pathology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China
| | - Yaohe Wang
- Sino-British Research Centre for Molecular Oncology, National Centre for International Research in Cell and Gene Therapy, Academy of Medical Sciences, Zhengzhou University, Henan, China.,Centre for Cancer Biomarkers and Biotherapeutics, Barts Cancer Institute, Queen Mary University, London, UK
| | - Zhongde Wang
- Department of Animal, Dairy, and Veterinary Sciences, Utah State University, Logan, Utah, USA
| | - Robert T Cormier
- Department of Biomedical Sciences, University of Minnesota Medical School, Duluth, MN, USA
| |
Collapse
|
2
|
Keel SB, Scott A, Sanchez-Bonilla M, Ho PA, Gulsuner S, Pritchard CC, Abkowitz JL, King MC, Walsh T, Shimamura A. Genetic features of myelodysplastic syndrome and aplastic anemia in pediatric and young adult patients. Haematologica 2016; 101:1343-1350. [PMID: 27418648 DOI: 10.3324/haematol.2016.149476] [Citation(s) in RCA: 102] [Impact Index Per Article: 12.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/16/2016] [Accepted: 07/13/2016] [Indexed: 11/09/2022] Open
Abstract
The clinical and histopathological distinctions between inherited versus acquired bone marrow failure and myelodysplastic syndromes are challenging. The identification of inherited bone marrow failure/myelodysplastic syndromes is critical to inform appropriate clinical management. To investigate whether a subset of pediatric and young adults undergoing transplant for aplastic anemia or myelodysplastic syndrome have germline mutations in bone marrow failure/myelodysplastic syndrome genes, we performed a targeted genetic screen of samples obtained between 1990-2012 from children and young adults with aplastic anemia or myelodysplastic syndrome transplanted at the Fred Hutchinson Cancer Research Center. Mutations in inherited bone marrow failure/myelodysplastic syndrome genes were found in 5.1% (5/98) of aplastic anemia patients and 13.6% (15/110) of myelodysplastic syndrome patients. While the majority of mutations were constitutional, a RUNX1 mutation present in the peripheral blood at a 51% variant allele fraction was confirmed to be somatically acquired in one myelodysplastic syndrome patient. This highlights the importance of distinguishing germline versus somatic mutations by sequencing DNA from a second tissue or from parents. Pathological mutations were present in DKC1, MPL, and TP53 among the aplastic anemia cohort, and in FANCA, GATA2, MPL, RTEL1, RUNX1, SBDS, TERT, TINF2, and TP53 among the myelodysplastic syndrome cohort. Family history or physical examination failed to reliably predict the presence of germline mutations. This study shows that while any single specific bone marrow failure/myelodysplastic syndrome genetic disorder is rare, screening for these disorders in aggregate identifies a significant subset of patients with inherited bone marrow failure/myelodysplastic syndrome.
Collapse
Affiliation(s)
- Siobán B Keel
- Department of Medicine, Division of Hematology, University of Washington, Seattle, WA, USA
| | - Angela Scott
- Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.,Department of Pediatric Hematology/Oncology, Seattle Children's Hospital, WA, USA.,Department of Pediatrics, University of Washington, Seattle, WA, USA
| | - Marilyn Sanchez-Bonilla
- Boston Children's Hospital, Dana Farber Cancer Institute, and Harvard Medical School, MA, USA
| | - Phoenix A Ho
- Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.,Department of Pediatric Hematology/Oncology, Seattle Children's Hospital, WA, USA.,Department of Pediatrics, University of Washington, Seattle, WA, USA
| | - Suleyman Gulsuner
- Department of Medicine and Department of Genome Sciences, University of Washington, Seattle, WA, USA
| | - Colin C Pritchard
- Department of Laboratory Medicine, University of Washington, Seattle, WA, USA
| | - Janis L Abkowitz
- Department of Medicine, Division of Hematology, University of Washington, Seattle, WA, USA
| | - Mary-Claire King
- Department of Medicine and Department of Genome Sciences, University of Washington, Seattle, WA, USA
| | - Tom Walsh
- Department of Medicine and Department of Genome Sciences, University of Washington, Seattle, WA, USA
| | - Akiko Shimamura
- Boston Children's Hospital, Dana Farber Cancer Institute, and Harvard Medical School, MA, USA
| |
Collapse
|
3
|
Synchronous Occurance of Acute Myeloid Leukemia and Rhabdomyosarcoma. Indian J Hematol Blood Transfus 2015; 31:387-90. [PMID: 26085727 DOI: 10.1007/s12288-014-0474-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/13/2014] [Accepted: 10/30/2014] [Indexed: 10/24/2022] Open
Abstract
Metachronous primary distinct tumors are frequently and increasingly encountered in oncology clinical practice of recent times, but synchronous tumours are still a rarity. We report an unusual case of a 2 year old male child who had synchronous occurrence of rhabdomyosarcoma of pelvis and acute myeloid leukemia.Our search of literature suggests that this may be the first reported case of simultaneous occurrence of these two malignancies.
Collapse
|
4
|
Leukocyte p53 protein biosignature through standard-aligned two-dimensional immunoblotting. J Proteomics 2012; 76 Spec No.:69-78. [PMID: 22842154 DOI: 10.1016/j.jprot.2012.07.021] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/28/2012] [Revised: 06/22/2012] [Accepted: 07/16/2012] [Indexed: 12/11/2022]
Abstract
Peripheral leukocytes may reflect systemic disease and stress states through their gene expression profile. Subsequent protein analyses of leukocytes are hypothesized to provide essential information regarding systemic diseases. We have developed a protein biosignature analysis of the tumour suppressor and cell stress sensor p53 based on two-dimensional gel electrophoresis and immunoblotting, and utilize fluorescently labelled reference standards to significantly improve the alignment and comparison of biosignatures, including full-length p53 and isoforms p53β and p53γ. Analysis of the p53 biosignatures of peripheral blood mononuclear cells from 526 healthy individuals and 65 acute myeloid leukaemia patients indicated a novel putative p53 protein variant in a subset of individuals (227 of 526 healthy tested). The p53 variant was more distinct in the reference standard aligned biosignatures of healthy individuals, compared to the non-standard aligned leukaemia biosignatures. This approximately 2 kDa heavier variant of p53 appeared with similar frequency in leukemic and healthy test persons, without coinciding with known splice forms or post-translational modifications of p53. We propose that a standardized leukocyte protein biosignature of p53 provides a powerful research tool and indicate how p53 protein biosignatures may be used in future diagnostics. This article is part of a Special Issue entitled: Integrated omics.
Collapse
|
5
|
Link DC, Schuettpelz LG, Shen D, Wang J, Walter MJ, Kulkarni S, Payton JE, Ivanovich J, Goodfellow PJ, Le Beau M, Koboldt DC, Dooling DJ, Fulton RS, Bender RHF, Fulton LL, Delehaunty KD, Fronick CC, Appelbaum EL, Schmidt H, Abbott R, O'Laughlin M, Chen K, McLellan MD, Varghese N, Nagarajan R, Heath S, Graubert TA, Ding L, Ley TJ, Zambetti GP, Wilson RK, Mardis ER. Identification of a novel TP53 cancer susceptibility mutation through whole-genome sequencing of a patient with therapy-related AML. JAMA 2011; 305:1568-76. [PMID: 21505135 PMCID: PMC3170052 DOI: 10.1001/jama.2011.473] [Citation(s) in RCA: 118] [Impact Index Per Article: 9.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/03/2023]
Abstract
CONTEXT The identification of patients with inherited cancer susceptibility syndromes facilitates early diagnosis, prevention, and treatment. However, in many cases of suspected cancer susceptibility, the family history is unclear and genetic testing of common cancer susceptibility genes is unrevealing. OBJECTIVE To apply whole-genome sequencing to a patient without any significant family history of cancer but with suspected increased cancer susceptibility because of multiple primary tumors to identify rare or novel germline variants in cancer susceptibility genes. DESIGN, SETTING, AND PARTICIPANT: Skin (normal) and bone marrow (leukemia) DNA were obtained from a patient with early-onset breast and ovarian cancer (negative for BRCA1 and BRCA2 mutations) and therapy-related acute myeloid leukemia (t-AML) and analyzed with the following: whole-genome sequencing using paired-end reads, single-nucleotide polymorphism (SNP) genotyping, RNA expression profiling, and spectral karyotyping. MAIN OUTCOME MEASURES Structural variants, copy number alterations, single-nucleotide variants, and small insertions and deletions (indels) were detected and validated using the described platforms. RESULTS; Whole-genome sequencing revealed a novel, heterozygous 3-kilobase deletion removing exons 7-9 of TP53 in the patient's normal skin DNA, which was homozygous in the leukemia DNA as a result of uniparental disomy. In addition, a total of 28 validated somatic single-nucleotide variations or indels in coding genes, 8 somatic structural variants, and 12 somatic copy number alterations were detected in the patient's leukemia genome. CONCLUSION Whole-genome sequencing can identify novel, cryptic variants in cancer susceptibility genes in addition to providing unbiased information on the spectrum of mutations in a cancer genome.
Collapse
MESH Headings
- Adult
- Age of Onset
- Breast Neoplasms/therapy
- Cystadenocarcinoma, Serous/therapy
- DNA, Neoplasm/genetics
- Female
- Genes, p53/genetics
- Genetic Predisposition to Disease
- Genome, Human/genetics
- Humans
- Leukemia, Myeloid, Acute/etiology
- Leukemia, Myeloid, Acute/genetics
- Ovarian Neoplasms/therapy
- Polymorphism, Single Nucleotide
- Sequence Analysis, DNA
- Sequence Deletion
- Tumor Suppressor Protein p53/genetics
Collapse
Affiliation(s)
- Daniel C. Link
- Department of Medicine, Siteman Cancer Center, Washington University, St. Louis, MO
| | | | - Dong Shen
- Department of Genetics, The Genome Center, Washington University, St. Louis, MO
| | - Jinling Wang
- Department of Biochemistry, St. Jude Children’s Research Hospital, Memphis, TN
| | - Matthew J. Walter
- Department of Medicine, Siteman Cancer Center, Washington University, St. Louis, MO
| | - Shashikant Kulkarni
- Department of Pediatrics, Washington University, St. Louis, MO
- Department of Genetics, The Genome Center, Washington University, St. Louis, MO
- Department of Pathology and Immunology, Siteman Cancer Center, Washington University, St. Louis, MO
| | - Jacqueline E. Payton
- Department of Pathology and Immunology, Siteman Cancer Center, Washington University, St. Louis, MO
| | | | | | | | - Daniel C. Koboldt
- Department of Genetics, The Genome Center, Washington University, St. Louis, MO
| | - David J. Dooling
- Department of Genetics, The Genome Center, Washington University, St. Louis, MO
| | - Robert S. Fulton
- Department of Genetics, The Genome Center, Washington University, St. Louis, MO
| | - R. Hugh F. Bender
- Department of Medicine, Siteman Cancer Center, Washington University, St. Louis, MO
| | - Lucinda L. Fulton
- Department of Genetics, The Genome Center, Washington University, St. Louis, MO
| | | | - Catrina C. Fronick
- Department of Genetics, The Genome Center, Washington University, St. Louis, MO
| | | | - Heather Schmidt
- Department of Genetics, The Genome Center, Washington University, St. Louis, MO
| | - Rachel Abbott
- Department of Genetics, The Genome Center, Washington University, St. Louis, MO
| | - Michelle O'Laughlin
- Department of Genetics, The Genome Center, Washington University, St. Louis, MO
| | - Ken Chen
- Department of Genetics, The Genome Center, Washington University, St. Louis, MO
| | - Michael D. McLellan
- Department of Genetics, The Genome Center, Washington University, St. Louis, MO
| | - Nobish Varghese
- Department of Pathology and Immunology, Siteman Cancer Center, Washington University, St. Louis, MO
| | - Rakesh Nagarajan
- Department of Pathology and Immunology, Siteman Cancer Center, Washington University, St. Louis, MO
| | - Sharon Heath
- Department of Medicine, Siteman Cancer Center, Washington University, St. Louis, MO
| | - Timothy A. Graubert
- Department of Medicine, Siteman Cancer Center, Washington University, St. Louis, MO
| | - Li Ding
- Department of Genetics, The Genome Center, Washington University, St. Louis, MO
| | - Timothy J. Ley
- Department of Medicine, Siteman Cancer Center, Washington University, St. Louis, MO
- Department of Genetics, The Genome Center, Washington University, St. Louis, MO
| | - Gerard P. Zambetti
- Department of Biochemistry, St. Jude Children’s Research Hospital, Memphis, TN
| | - Richard K. Wilson
- Department of Genetics, The Genome Center, Washington University, St. Louis, MO
| | - Elaine R. Mardis
- Department of Genetics, The Genome Center, Washington University, St. Louis, MO
| |
Collapse
|
6
|
Grover R, Candeias MM, Fåhraeus R, Das S. p53 and little brother p53/47: linking IRES activities with protein functions. Oncogene 2009; 28:2766-72. [DOI: 10.1038/onc.2009.138] [Citation(s) in RCA: 42] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/26/2022]
|